

# **Assessing Hypotension Incidence and Dosing Strategies of Sacubitril/Valsartan in Real-World Heart Failure Management: Protocol for A Retrospective, Multicenter, Cohort Study**

Uday M Jadhav, Arun Mohanty, Jay Shah, M Chenniappan, K. Naveen Krishna, Ameet G. Sattur, Mainak Mukhopadhyay

Submitted to: JMIR Research Protocols  
on: May 18, 2024

**Disclaimer:** © The authors. All rights reserved. This is a privileged document currently under peer-review/community review. Authors have provided JMIR Publications with an exclusive license to publish this preprint on its website for review purposes only. While the final peer-reviewed paper may be licensed under a CC BY license on publication, at this stage authors and publisher expressly prohibit redistribution of this draft paper other than for review purposes.

*Table of Contents*

**Original Manuscript..... 5**  
**Supplementary Files..... 13**  
    Figures ..... 14  
        Figure 1..... 15

# Assessing Hypotension Incidence and Dosing Strategies of Sacubitril/Valsartan in Real-World Heart Failure Management: Protocol for A Retrospective, Multicenter, Cohort Study

Uday M Jadhav<sup>1</sup>; Arun Mohanty<sup>2</sup>; Jay Shah<sup>3</sup>; M Chenniappan<sup>4</sup>; K. Naveen Krishna<sup>5</sup>; Ameet G. Sattur<sup>6</sup>; Mainak Mukhopadhyay<sup>7</sup>

<sup>1</sup>MGM New Bombay Hospital, Mumbai Navi Mumbai IN

<sup>2</sup>Sir Ganga Ram Hospital, New Delhi New Delhi IN

<sup>3</sup>Krish Heart Care, Ahmedabad Ahmedabad IN

<sup>4</sup>Ramakrishna Medical Centre LLP(Heart Care Unit) Trichy Trichy IN

<sup>5</sup>Aditya Health Clinics, Hyderabad Hyderabad IN

<sup>6</sup>Sattur Heart Care, Hubli Hubli IN

<sup>7</sup>Amri Hopsital, Salt lake, Kolkata Kolkata IN

## Corresponding Author:

Uday M Jadhav

MGM New Bombay Hospital, Mumbai

Plot No.35, Atmashanti Society, Sector 3, Vashi

Navi Mumbai

IN

## Abstract

**Background:** The burden of heart failure (HF) and hypertension in India underscores the need for effective management strategies. Sacubitril/valsartan, an angiotensin receptor neprilysin inhibitor (ARNi), has emerged as a pivotal therapy for HF with reduced ejection fraction (HFrEF). However, concerns about hypotension often hinder optimal dosing in clinical practice. The objective of this study is to observe the incidence of hypotension in HFrEF patients and to evaluate the best clinical practice to achieve an optimal tolerated dose of sacubitril/valsartan without treatment discontinuation.

**Objective:** The primary aim of this study is to evaluate the incidence of hypotension among HFrEF patients receiving sacubitril/valsartan and assess the feasibility of dose titration to achieve optimal tolerated doses in real-world settings. Secondary objectives include evaluating treatment outcomes, tolerability, and factors influencing dosing adjustments.

**Methods:** This is the protocol of a retrospective, multicenter cohort study aimed at assessing real-world usage patterns of sacubitril/valsartan among Indian HFrEF patients, focusing on hypotension occurrence and optimal dose attainment. Patients aged 18-80 years diagnosed with HFrEF (left ventricular ejection fraction (LVEF) < 40%) and initiated on sacubitril/valsartan between November 2023 and May 2024 will be included. Baseline and follow-up data, including demographics, medical history, and treatment outcomes, will be analyzed using appropriate statistical tests. Data from approximately 150 healthcare facilities will be collected using a structured Case Report Form (CRF).

**Results:** The study was initiated in February 2024. As of manuscript submission, 892 individuals have been recruited, with data collection expected to conclude by the end of May and results anticipated by June.

**Conclusions:** This study aims to contribute valuable insights into optimizing sacubitril/valsartan therapy for HFrEF patients in India, addressing concerns about hypotension and dosage optimization. The study seeks to inform clinical practice and enhance patient care by elucidating real-world usage patterns and outcomes Clinical Trial: Nil

(JMIR Preprints 18/05/2024:60640)

DOI: <https://doi.org/10.2196/preprints.60640>

## Preprint Settings

1) Would you like to publish your submitted manuscript as preprint?

✓ Please make my preprint PDF available to anyone at any time (recommended).

Please make my preprint PDF available only to logged-in users; I understand that my title and abstract will remain visible to all users.  
Only make the preprint title and abstract visible.

No, I do not wish to publish my submitted manuscript as a preprint.

2) If accepted for publication in a JMIR journal, would you like the PDF to be visible to the public?

✓ **Yes, please make my accepted manuscript PDF available to anyone at any time (Recommended).**

Yes, but please make my accepted manuscript PDF available only to logged-in users; I understand that the title and abstract will remain visible to all users.

Yes, but only make the title and abstract visible (see Important note, above). I understand that if I later pay to participate in <http://www.jmir.org/preprint/60640>, my full manuscript will be made available to all users.



## Original Manuscript

## Protocol

# Assessing Hypotension Incidence and Dosing Strategies of Sacubitril/Valsartan in Real-World Heart Failure Management: Protocol for a Retrospective, Multicenter, Cohort Study

Uday M. Jadhav<sup>1</sup>, Arun Mohanty<sup>2</sup>, Jay Shah<sup>3</sup>, M. Chenniappan<sup>4</sup>, K. Naveen Krishna<sup>5</sup>, Ameet G. Sattur<sup>6</sup>, Mainak Mukhopadhyay<sup>7</sup>

<sup>1</sup> Cardiology and Cardiac CT Department, MGM New Bombay Hospital, Mumbai, India

<sup>2</sup> Senior Consultant & Director Intra Vascular Imaging, Sir Ganga Ram Hospital, New Delhi, India

<sup>3</sup> Interventional Cardiologist & Angiologist, Krish Heart Care, Ahmedabad, India

<sup>4</sup> Consultant Cardiologist, Ramakrishna Medical Centre LLP (Heart Care Unit) Trichy, India

<sup>5</sup> Consultant Interventional Cardiologist, Aditya Health Clinics, Hyderabad, India

<sup>6</sup> Interventional Cardiologist, Sattur Heart Care, Hubli, India

<sup>7</sup> Consultant Interventional Cardiologist, Amri Hospital, Salt lake, Kolkata, India

## Corresponding author:

Dr. Uday M. Jadhav,

**Address:** MGM New Bombay Hospital, Mumbai

**Email id:** umjadhav@gmail.com

**Keywords:** Sacubitril/valsartan, Heart Failure, Reduced Ejection Fraction, Real-world evidence, blood pressure, tolerability, effectiveness.

## Abstract

**Background:** The burden of heart failure (HF) and hypertension in India underscores the need for effective management strategies. Sacubitril/valsartan, an angiotensin receptor neprilysin inhibitor (ARNi), has emerged as a pivotal therapy for HF with reduced ejection fraction (HFrEF). However, concerns about hypotension often hinder optimal dosing in clinical practice. The objective of this study is to observe the incidence of hypotension in HFrEF patients and to evaluate the best clinical practice to achieve an optimal tolerated dose of sacubitril/valsartan without treatment discontinuation.

**Objective:** The primary aim of this study is to evaluate the incidence of hypotension among HFrEF patients receiving sacubitril/valsartan and assess the feasibility of dose titration to achieve optimal tolerated doses in real-world settings. Secondary objectives include evaluating treatment outcomes, tolerability, and factors influencing dosing adjustments.

**Methods:** This is the protocol of a retrospective, multicenter cohort study aimed at assessing real-world usage patterns of sacubitril/valsartan among Indian HFrEF patients, focusing on hypotension occurrence and optimal dose attainment. Patients aged 18-80 years diagnosed with HFrEF (left ventricular ejection fraction (LVEF)  $\leq 40\%$ ) and initiated on sacubitril/valsartan between November 2023 and May 2024 will be included. Baseline and follow-up data, including demographics, medical history, and treatment outcomes, will be analyzed using appropriate statistical tests. Data from approximately 150 healthcare facilities will be collected using a structured Case Report Form (CRF).

**Results:** The study was initiated in February 2024. As of manuscript submission, 892 individuals have been recruited, with data collection expected to conclude by the end of May and results anticipated by June.

**Conclusion:** This study aims to contribute valuable insights into optimizing

sacubitril/valsartan therapy for HFrEF patients in India, addressing concerns about hypotension and dosage optimization. The study seeks to inform clinical practice and enhance patient care by elucidating real-world usage patterns and outcomes.

## Introduction

Heart failure (HF) imposes a significant burden in India, with prevalence estimates ranging from 1.3 million to 4.6 million and an annual incidence of 491,600–1.8 million (1). Trivandrum Heart Failure Registry data revealed that HF with reduced ejection fraction (HFrEF) was the most common subtype (62%), followed by HF with preserved ejection fraction (HFpEF) (20%) and HF with mid-range ejection fraction (18%), with an in-hospital mortality rate of 8.4%. Hypertension emerges as a significant contributor to HF, present in 55% of cases according to the registry, making it the second most common cause after ischemic heart disease (72%) (2). The prevalence of hypertension is projected to increase from 118 million (2000) to 214 million (2025), potentially leading to an increase in HF cases associated with hypertension(1).

As per the 2022 American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America (ACC/AHA/HFSA) Focused Update on New Pharmacological Therapy for HF, ACEI, ARB, or angiotensin receptor neprilysin inhibitor (ARNi) are now advocated for patients with chronic symptomatic HFrEF to mitigate morbidity and mortality, receiving a class I recommendation (3).

Sacubitril/valsartan is superior to enalapril in reducing the risks of cardiovascular death and preventing hospitalization in patients with HFrEF(4,5). The use of Sacubitril/Valsartan in HFrEF patients is associated with a significant reduction in blood pressure (BP) as compared to the ACEI/ARB group overall and across the eGFR spectrum, including in advanced chronic kidney disease(4,6–8).The suggested initial dose of sacubitril/valsartan is 50 mg, to be taken orally twice daily. After a period of 2–4 weeks, the dosage can be increased to 100 mg and further escalated to 200 mg based on the individual's tolerance(9).

However, concerns about hypotension often lead to suboptimal dosing in patients despite evidence supporting its efficacy(10,11).The risk of hypotension poses a significant challenge to sacubitril/valsartan use, particularly in HFrEF patients, as demonstrated by retrospective studies and clinical trials(10). The primary objectives of this retrospective study are to evaluate hypotension incidence among HFrEF patients and analyze real-world clinical practice to achieve an optimal tolerated dose of sacubitril/valsartan without treatment discontinuation. The secondary objective is to evaluate the tolerability of Sacubitril/Valsartan 200mg BID after two months of treatment and dose adjustment (up-titration and down-titration) in HFrEF management.

## Methods

### Study design

The ongoing study adopts a retrospective, multicenter cohort design to investigate the real-world utilization patterns of sacubitril/valsartan among adult patients diagnosed with HFrEF in India. In this retrospective real-world evidence study, patient-informed consent is not required. The study will be initiated after the Ethics Committee's approval. The study aims to comprehensively assess how sacubitril/valsartan is used in clinical practice settings across multiple centers, providing valuable insights into its application, dosing strategies, and associated outcomes.

## Study participants

In the ongoing study, the patient population to be screened comprises individuals meeting specific inclusion and exclusion criteria to ensure the relevance and integrity of the research findings. The target population includes adult patients with HFrEF who have been prescribed sacubitril/valsartan and are visiting practicing clinicians in an outpatient (OP) setting within the specified timeframe.

The inclusion criteria are age 18 to 80 years, of either gender, diagnosed with HFrEF defined by a LVEF of  $\leq 40\%$ , and categorized as New York Heart Association (NYHA) functional class II-IV. Furthermore, individuals must have initiated sacubitril/valsartan therapy between November 2023 and May 2024, and the medication should have been prescribed either at the time of discharge from a healthcare facility or during an OP consultation.

The following patients will be excluded from the data analysis: diagnosis of HFpEF, HF predominantly resulting from right ventricular failure, pericardial disease, or congenital heart disease, and patients with missing follow-up data.

By adhering to these stringent criteria, the study aims to focus specifically on HFrEF patients who have received sacubitril/valsartan in the OP setting, thereby ensuring homogeneity within the study population, and facilitating accurate assessment of real-world usage patterns, treatment outcomes, and associated factors.

## Data collection and follow-up

In this study protocol, data collection is facilitated through the extraction of patient data onto CRF. Through a retrospective approach, data from medical records of eligible patients who have been prescribed sacubitril/valsartan for the management of HFrEF are systematically extracted and documented onto the CRF. This data collection process spans 160 centers across India, offering a diverse representation of real-world clinical practices and patient populations (Figure 1).

To ensure adherence to stringent quality control standards, research coordinators will receive extensive training on the study protocol and procedures for extracting data from medical records before initiating data collection. Data security remains of utmost importance throughout the study, with access restricted solely to authorized personnel.

## Data items

The CRF will serve as a standardized tool for systematically capturing pertinent information regarding the selected cases, including patient demographic details, medical history, baseline characteristics, treatment regimens, dosing adjustments, adverse events, and clinical outcomes. All adverse events and reactions and their management will be recorded in the CRF.

## Outcome measures

The primary outcomes are changes in both systolic and diastolic BP across different postures (sitting, lying, standing), alterations in NYHA class, percentage of patients Sacubitril/Valsartan 200mg twice daily after two months of treatment initiation. Additionally, the study will retrospectively assess the tolerability of Sacubitril/Valsartan.

Furthermore, secondary endpoints will be evaluated to provide additional insights into the current utilization of Sacubitril/Valsartan. These secondary outcomes include assessing changes in clinical signs and symptoms of HF, changes in NT-proBNP levels (if data is available), determining the percentage of patients requiring down-titration of Sacubitril/Valsartan (from 200mg to 100 mg; 100mg to 50mg; and 50mg to 0mg (i.e., treatment discontinuation), and identifying reasons for down-titration or treatment discontinuation. Additionally, the study will analyze the time taken for patients to reach each up-titration level of Sacubitril/Valsartan



(100mg and 200mg) and the median time required to achieve the maximum dosage of Sacubitril/Valsartan, i.e., 200mg twice daily. These comprehensive endpoints collectively aim to provide a thorough evaluation of Sacubitril/Valsartan therapy in managing HF while also assessing its tolerability and potential dose adjustments in clinical practice.

## Statistical Analysis

Demographic and other qualitative parameters, such as age, gender distribution, comorbidities, and treatment adherence, will be summarized using frequency and percentage tables. This approach will offer a comprehensive overview of the patient population under investigation, allowing for the identification of any notable trends or associations.

Quantitative parameters, including BP and pulse rate, will undergo analysis using the paired t-test, contingent upon the satisfaction of normality assumptions. This statistical test will enable the comparison of pre- and post-treatment measurements within each patient, thereby assessing the impact of sacubitril/valsartan therapy on physiological parameters.

For qualitative parameters measured on an ordinal scale, such as NYHA class or severity of symptoms, the Wilcoxon Signed Rank Test will be employed. This non-parametric test is suitable for analyzing paired data with an ordinal or graded structure, allowing for the assessment of treatment-induced changes in subjective endpoints.

Observations from the study cohort will be summarized using descriptive statistics, including measures such as mean, standard deviation, median, and interquartile range. These statistics will provide a concise summary of continuous variables' central tendency and variability, offering insights into the overall effectiveness and tolerability of sacubitril/valsartan therapy in real-world clinical settings.

## Results

The study was initiated in February 2024. As of the submission of this manuscript, 892 individuals have been enrolled into the study. Data collection is expected to continue until the end of May 2024, with the analysis and interpretation of results anticipated to be completed by the end of June.

## Discussion

If the annual incidence of HF in patients with systolic blood pressure (SBP) of 144–154 mmHg is 0.1% to 0.6%, as demonstrated in the Hypertension Optimal Treatment and United Kingdom Prospective Diabetes Study trials, respectively, then the number of new HF cases due to hypertension may increase from 118 000–708 000 per year in 2000 to 214 000–1.3 million per year in 2025, conservatively assuming that the bulk of patients with hypertension in India have a SBP in the 144–154 mmHg range. After 5 years of HF incidence based upon the year 2000 estimates for hypertension, the total number of HF patients accrued could range from 590,000 to 3.5 million; with an estimated 50% mortality at 5 years, the prevalence of HF due to hypertension alone could be estimated to range from 295 000 to 1.8 million. However, this possibly represents an underestimate due to conservative estimates of the prevalence of hypertension, as well as the linear relationship between the risk of HF and BP that occurs for values even <140 mmHg(1).

The introduction of Sacubitril/valsartan represents a significant advancement in HF management, as highlighted by leading cardiovascular guidelines for its efficacy in reducing morbidity and mortality among patients with chronic symptomatic HFrEF. As the first agent in

the ARNi class, Sacubitril/valsartan is FDA-approved for HFrEF patients with NYHA class II, III, or IV symptoms, offering a valuable alternative to ACE inhibitors or ARBs. Its integration alongside standard HF therapies has demonstrated significant BP reduction compared to ACEIs/ARBs, even in patients with advanced chronic kidney disease. Sacubitril/valsartan has shown superiority over enalapril in reducing cardiovascular death risks and preventing hospitalizations in HFrEF patients (3,12).

Achieving optimal dosing of Sacubitril/valsartan can be challenging due to concerns regarding hypotension, which often leads to potential treatment discontinuation. Despite these challenges, Sacubitril/valsartan remains a cornerstone of HF therapy and an essential component of guideline-directed medical treatment (10,13).

Recognizing the importance of optimizing Sacubitril/valsartan dosing in real-world settings, this study aims to evaluate the incidence of hypotension among HFrEF patients and assess the feasibility of dose titration to achieve optimal tolerated doses. This study holds several strengths, including its status as one of the pioneering real-world investigations into Sacubitril/valsartan's efficacy and safety. It aims to identify barriers hindering the attainment of target doses and reasons for treatment discontinuation, thereby contributing to a better understanding of treatment adherence, persistence, epidemiology, and prescribing patterns. Through this study, clinicians can enhance their knowledge of Sacubitril/valsartan utilization and its impact on HF patient outcomes, ultimately improving treatment strategies and patient care.

## Conclusion

In summary, this study delves into real-world applications of sacubitril/valsartan therapy in HFrEF patients, aiming to optimize treatment outcomes by assessing dosing strategies and hypotension incidence. With HF and hypertension burdens rising in India, the study's insights hold promise for informing clinical guidelines and enhancing patient care. Overall, tailored dosing strategies and vigilant monitoring are emphasized to improve sacubitril/valsartan therapy efficacy and patient quality of life in HFrEF management.

## Acknowledgements

The grant for the study was provided by Mankind. IntelliMed Healthcare Solutions Pvt. Ltd., India supported in manuscript writing and submission.

## Authors' Contributions

UJ, AM and JS conceptualized the study and developed the draft. MC, KNK, AGS and MM contributed substantially by reviewing and editing the protocol manuscript. All authors read and approved the final study protocol.

## Conflicts of interest

None declared.

## Abbreviations

HF: Heart Failure

ARNi : Angiotensin receptor-Neprilysin inhibitor  
HFrEF: Heart failure with reduced ejection fraction  
LVEF: Left ventricular ejection fraction  
CRF: Case Record Form  
HFpEF: Heart failure with preserved ejection fraction  
ACC: American College of Cardiology  
AHA: American Heart Association  
HFSA: Heart Failure Society of America  
OP: Outpatient  
NYHA: New York Heart Association  
SBP: Systolic Blood Pressure

## References

1. HUFFMAN MD, PRABHAKARAN D. Heart failure: Epidemiology and prevention in India. *Natl Med J India*. 2010;23(5):283–8. PMID: 21250584
2. Harikrishnan S, Sanjay G, Anees T, Viswanathan S, Vijayaraghavan G, Bahuleyan CG, et al. Clinical presentation, management, in-hospital and 90-day outcomes of heart failure patients in Trivandrum, Kerala, India: the Trivandrum Heart Failure Registry. *Eur J Heart Fail*. 2015 Aug;17(8):794–800. PMID: 26011246
3. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2022 May 3;145(18):e895–1032. DOI: <https://doi.org/10.1161/CIR.0000000000001063>
4. McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure. *N Engl J Med*. 2014 Sep 11;371(11):993–1004. PMID: 25176015 DOI: 10.1056/NEJMoa1409077
5. Pereira SC, Rodrigues T, Nunes-Ferreira A, Agostinho JR, Pinto FJ, Brito D. Effectiveness and Safety of Sacubitril/Valsartan in Patients with Chronic Kidney Disease—A Real-World Experience. *Journal of Clinical Medicine*. 2023 Jan;12(4):1334. PMID: 36835870
6. Niu C, Yang S, Ou S, Wu C, Huang P, Hung C, et al. Sacubitril/Valsartan in Patients With Heart Failure and Concomitant End-Stage Kidney Disease. *Journal of the American Heart Association*. 2022 Sep 20;11(18):e026407. DOI: <https://doi.org/10.1161/JAHA.122.026407>
7. Hsiao FC, Lin CP, Yu CC, Tung YC, Chu PH. Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction and Advanced Chronic Kidney Disease: A Retrospective Multi-Institutional Study. *Front Cardiovasc Med*. 2022 Mar 8;9:794707. PMID: 35360037
8. Chang HY, Feng AN, Fong MC, Hsueh CW, Lai WT, Huang KC, et al. Sacubitril/valsartan in heart failure with reduced ejection fraction patients: Real world experience on advanced chronic kidney disease, hypotension, and dose escalation. *Journal of Cardiology*. 2019 Oct 1;74(4):372–80. PMID: 30982680

9. Dalal J, Chandra P, Ray S, Hazra PK, Hiremath J, Kumar V, et al. Practical Recommendations for the Use of Angiotensin Receptor-Neprilysin Inhibitors (ARNI) in Heart Failure: Insights from Indian Cardiologists. *Cardiol Ther*. 2023 Sep;12(3):445–71. PMID: 37382802
10. Kim H, Oh J, Lee S, Ha J, Yoon M, Chun K hyeon, et al. Clinical evidence of initiating a very low dose of sacubitril/valsartan: a prospective observational analysis. *Sci Rep*. 2021 Aug 11;11:16335. PMID: 34381126
11. Park JJ, Lee SE, Cho HJ, Choi JO, Yoo BS, Kang SM, et al. Real-World Usage of Sacubitril/Valsartan in Korea: A Multi-Center, Retrospective Study. *Int J Heart Fail*. 2022 Oct 25;4(4):193–204. DOI: <https://doi.org/10.36628/ijhf.2022.0015>
12. Classes and Stages of Heart Failure. Available from: <https://www.heart.org/en/health-topics/heart-failure/what-is-heart-failure/classes-of-heart-failure>
13. Ehteshami-Afshar S, Mooney L, Dewan P, Desai AS, Lang NN, Lefkowitz MP, et al. Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF. *J Am Heart Assoc*. 2021 Feb 16;10(4):e019238. PMID: 33522249

## Supplementary Files

## Figures

160 participating centers in India.

